These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1561919)

  • 1. Postmarketing surveillance of adverse drug reactions: patient self-monitoring.
    Fisher S; Bryant SG
    J Am Board Fam Pract; 1992; 5(1):17-25. PubMed ID: 1561919
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of age on reporting of adverse clinical events: results from two postmarketing surveillance methods.
    Bryant SG; Fisher S; Prinsley DM; Olins NJ; Larson DB
    Pharmacotherapy; 1991; 11(3):249-55. PubMed ID: 1862016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-initiated postmarketing surveillance: a validation study.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    J Clin Pharmacol; 1987 Nov; 27(11):843-54. PubMed ID: 3429691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outliers and patients with adverse drug reactions.
    Edwards IR
    Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous adverse reactions to psychotropic drugs: data from a multicenter surveillance program.
    Lange-Asschenfeldt C; Grohmann R; Lange-Asschenfeldt B; Engel RR; Rüther E; Cordes J
    J Clin Psychiatry; 2009 Sep; 70(9):1258-65. PubMed ID: 19538904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in perceived and presented adverse drug reactions in general practice.
    Ottervanger JP; Valkenburg HA; Grobbee DE; Stricker BH
    J Clin Epidemiol; 1998 Sep; 51(9):795-9. PubMed ID: 9731928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescription-event monitoring in Japan (J-PEM).
    Kubota K
    Drug Saf; 2002; 25(6):441-4. PubMed ID: 12071781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmarketing surveillance for drug abuse.
    Arfken CL; Cicero TJ
    Drug Alcohol Depend; 2003 Jun; 70(3 Suppl):S97-105. PubMed ID: 12759200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utilization and challenges of Japan's MID-NET
    Yamada K; Itoh M; Fujimura Y; Kimura M; Murata K; Nakashima N; Nakayama M; Ohe K; Orii T; Sueoka E; Suzuki T; Yokoi H; Ishiguro C; Uyama Y;
    Pharmacoepidemiol Drug Saf; 2019 May; 28(5):601-608. PubMed ID: 30945387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety monitoring of new anti-malarials in immediate post-marketing phase.
    Edwards IR
    Med Trop (Mars); 1998; 58(3 Suppl):93-6. PubMed ID: 10212911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients as a direct source of information on adverse drug reactions.
    Mitchell AS; Henry DA; Sanson-Fisher R; O'Connell DL
    BMJ; 1988 Oct; 297(6653):891-3. PubMed ID: 3140967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug makers' adverse event reports are often incomplete, US report finds.
    McCarthy M
    BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
    [No Abstract]   [Full Text] [Related]  

  • 15. A distributed, collaborative intelligent agent system approach for proactive postmarketing drug safety surveillance.
    Ji Y; Ying H; Farber MS; Yen J; Dews P; Miller RE; Massanari RM
    IEEE Trans Inf Technol Biomed; 2010 May; 14(3):826-37. PubMed ID: 20007038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel statistical tools for monitoring the safety of marketed drugs.
    Almenoff JS; Pattishall EN; Gibbs TG; DuMouchel W; Evans SJ; Yuen N
    Clin Pharmacol Ther; 2007 Aug; 82(2):157-66. PubMed ID: 17538548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug surveillance: concepts, objectives, and methods].
    Susano RC; Laborinho Fialho L; de Quirós JF
    Acta Med Port; 1992 Dec; 5(11):595-602. PubMed ID: 1293954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience in the development of a postmarketing surveillance network: the pharmacy medication monitoring program.
    Willison DJ; Gaebel KA; Borden EK; Levine MA; Poston JW; Goldsmith CH; Wong B
    Ann Pharmacother; 1995 Dec; 29(12):1208-13. PubMed ID: 8672822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA
    Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.